A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Clinical trial NCT07430202 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07430202
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))

Start date: 2026-08-01
Primary completion: 2030-08-01
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.